Sysmex (OTCMKTS:SSMXY) Announces Earnings Results, Beats Expectations By $0.02 EPS

Sysmex (OTCMKTS:SSMXY) announced its earnings results on Friday. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02, Zacks reports. Sysmex had a return on equity of 7.23% and a net margin of 7.13%. Sysmex updated its FY 2026 guidance to 0.382-0.382 EPS.

Sysmex Trading Up 6.2%

SSMXY traded up $0.64 during trading on Friday, hitting $10.94. The company’s stock had a trading volume of 31,586 shares, compared to its average volume of 214,687. Sysmex has a twelve month low of $8.01 and a twelve month high of $14.20. The stock has a market cap of $6.89 billion, a PE ratio of 28.79 and a beta of 1.05. The firm’s 50 day moving average price is $9.34 and its 200-day moving average price is $9.06. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.